FDA cites an ‘ongoing review’ for Pfizer's blockbuster Xeljanz, with implications for the class
On Wednesday a Pfizer representative told Endpoints News that the pharma giant had no immediate plans to take any new actions related to the marketing of their blockbuster drug Xeljanz. But it’s not entirely in their hands.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 64,800+ biopharma pros reading Endpoints daily — and it's free.